ATE358486T1 - Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion - Google Patents
Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektionInfo
- Publication number
- ATE358486T1 ATE358486T1 AT01983374T AT01983374T ATE358486T1 AT E358486 T1 ATE358486 T1 AT E358486T1 AT 01983374 T AT01983374 T AT 01983374T AT 01983374 T AT01983374 T AT 01983374T AT E358486 T1 ATE358486 T1 AT E358486T1
- Authority
- AT
- Austria
- Prior art keywords
- xestospongin
- treat
- hiv infection
- receptor
- calcium channel
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- PQYOPBRFUUEHRC-UHFFFAOYSA-N ent-xestospongin A Natural products C1CCCCCC(OC23)CCN3CCCC2CCCCCCC(O2)CCN3C2C1CCC3 PQYOPBRFUUEHRC-UHFFFAOYSA-N 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- PQYOPBRFUUEHRC-MUJQFDPKSA-N xestospongin c Chemical compound C([C@@H]1CCCN2CC[C@@H](O[C@H]12)CCCCCC1)CCCCC[C@H](O2)CCN3[C@H]2[C@@H]1CCC3 PQYOPBRFUUEHRC-MUJQFDPKSA-N 0.000 title 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 3
- 108091008585 IP3 receptors Proteins 0.000 abstract 3
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 abstract 3
- 239000000480 calcium channel blocker Substances 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24676300P | 2000-11-09 | 2000-11-09 | |
| US09/878,918 US20020107193A1 (en) | 2000-11-09 | 2001-06-13 | Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
| US30786001P | 2001-07-27 | 2001-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358486T1 true ATE358486T1 (de) | 2007-04-15 |
Family
ID=27399962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01983374T ATE358486T1 (de) | 2000-11-09 | 2001-11-08 | Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1331932B1 (de) |
| AT (1) | ATE358486T1 (de) |
| AU (1) | AU2002214886A1 (de) |
| CA (1) | CA2427757A1 (de) |
| DE (1) | DE60127703D1 (de) |
| WO (1) | WO2002038140A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444981A1 (de) | 2001-10-11 | 2004-08-11 | Katsuhiko Mikoshiba | Mittel zur unterdrückung der zunahme der intrazellulären calciumkonzentration |
| JP5360635B2 (ja) * | 2005-11-25 | 2013-12-04 | 独立行政法人科学技術振興機構 | 新規ビスホウ素化合物 |
| CA2642508C (en) | 2008-10-31 | 2011-10-04 | Kenneth W. Adams | Method of removal of hyperplastic skin lesions |
| CA3013734C (en) | 2009-12-03 | 2020-01-14 | Dr. Kenneth Adams Medicine Professional Corporation | Method and composition for treatment and prevention of broad spectrum virus ailments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59227885A (ja) * | 1983-06-09 | 1984-12-21 | Suntory Ltd | １−オキサキノリチジン類 |
| ES2053953T3 (es) * | 1988-08-24 | 1994-08-01 | Akzo Nv | Uso de fracciones de heparina o fragmentos de heparina. |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
| DE69215588T2 (de) * | 1991-06-26 | 1997-05-15 | Hoechst Ag | Inositol-Phosphat-Analog als kalzium-antagonistische Substanz |
| JPH08502068A (ja) * | 1992-09-28 | 1996-03-05 | メレルダウファーマスーティカルズ インコーポレイテッド | イノシトール１，４，５‐トリスホスフェートを拮抗する方法 |
| GB9515469D0 (en) * | 1995-07-28 | 1995-09-27 | Pharma Mar Sa | Bis-1-oxaquinolizidine alkaloids from a marine sponge with antitumor activity |
| US6465211B1 (en) * | 1998-08-27 | 2002-10-15 | Riken | Nucleic acids, vectors and transformed cells for making and using high affinity IP-3 binding polypeptides |
| US6027731A (en) * | 1998-11-17 | 2000-02-22 | Wisconsin Alumni Research Foundation | Pertussis toxin induced lymphocytosis |
-
2001
- 2001-11-08 AT AT01983374T patent/ATE358486T1/de not_active IP Right Cessation
- 2001-11-08 WO PCT/CA2001/001575 patent/WO2002038140A2/en not_active Ceased
- 2001-11-08 DE DE60127703T patent/DE60127703D1/de not_active Expired - Lifetime
- 2001-11-08 CA CA002427757A patent/CA2427757A1/en not_active Abandoned
- 2001-11-08 AU AU2002214886A patent/AU2002214886A1/en not_active Abandoned
- 2001-11-08 EP EP01983374A patent/EP1331932B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2427757A1 (en) | 2002-05-16 |
| EP1331932B1 (de) | 2007-04-04 |
| EP1331932A2 (de) | 2003-08-06 |
| WO2002038140A3 (en) | 2003-03-13 |
| DE60127703D1 (de) | 2007-05-16 |
| AU2002214886A1 (en) | 2002-05-21 |
| WO2002038140A2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE59409832D1 (de) | Pflaster zur behandlung von nagelmykosen | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DK0634927T3 (da) | Behandling og profylakse af sygdomme forårsaget af parasitter eller bakterier | |
| DE60101265D1 (de) | Behandlung von augenschmerzen | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| ATE358486T1 (de) | Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion | |
| WO2023240199A3 (en) | Fitusiran for the treatment of hemophilia a and b | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE401888T1 (de) | Verwendung von tigecyclin, allein oder in kombination mit rifampin zur behandlung von osteomyelitis und/oder septischer arthritis | |
| NO20032406L (no) | Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE270895T1 (de) | Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| ATE412423T1 (de) | Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| WO2025147672A3 (en) | Compositions and methods of use thereof | |
| ATE486594T1 (de) | Methode zur behandlung von herzinsuffizienz | |
| DE60108241D1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz | |
| DE10080190D2 (de) | Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs | |
| DE50107498D1 (de) | Verwendung einer zubereitung zur topischen behandlung von durch virusinfektionen verursachten manifestationen | |
| ATE439136T1 (de) | Verfahren zur behandlung von halitose | |
| UA42335A (uk) | Спосіб лікування гнійних ран | |
| ATE266403T1 (de) | Verwendung von 2-methyl-thiazolidin 2,4- dicarbonsäure zur herstellung eines medikaments zur behandlung von infektionskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |